Mavorixafor
Mavorixafor (AMD-070) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively. Mavorixafor can be used for the study of WHIM syndrome[1].
Product Specifications
CAS Number
558447-26-0
Product Name Alternative
AMD-070; AMD-11070
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
CXCR; HIV
Type
Reference compound
Related Pathways
Anti-infection; GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Infection; Endocrinology; Cancer
Assay Protocol
https://www.medchemexpress.com/amd-070.html
Purity
99.47
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NCCCCN(CC1=NC2=C(N1)C=CC=C2)[C@@H]3C4=C(CCC3)C=CC=N4
Molecular Formula
C21H27N5
Molecular Weight
349.47
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CXCR4; HIV-1
Citation 01
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Mouse Flt-3 Ligand protein (His Tag)
Recombinant Mouse Flt-3 Ligand protein (His Tag)
Sodium 2,3-Dimercaptopropanesulfonate Monohydrate
RNA Polymerase II (CTD4H8), CF647 conjugate, 0.1mg/mL
